Filing status
- Accounts due
- 31 December 2026
- Last accounts
- 31 May 2025
- Conf. stmt due
- 26 May 2027
- Last conf. stmt
- 12 May 2026
Ascension Earth Resources Ltd
- Incorporated
- 13 May 2024 (2 years)
- Industry
- Mining of other non-ferrous metal ores (07290)
- Directors
- Bradley Barry DoigMotoaki Sumi
- Owned by
- Accounts type
- Total exemption full
- Region
- South East
- Address
- Building F5 Culham CampusUnited Kingdom Atomic Energy AuthorityAbingdonOX14 3DB
Charges
- Total
- 1
- Outstanding
- 0
- Part satisfied
- 0
- Satisfied
- 1
Officers
This list may be incomplete. See all officers on Companies House
Officer details are public data from the Companies House register.
Doig, Bradley Barry
Director · Appointed 14 September 2026
British
Born September 1964 (62)
Director · Appointed 29 July 2025
American
Born January 1995 (31)
Sumi, Motoaki
Director · Appointed 13 May 2024
Japanese
Born September 1986 (40)
Blundy, Jonathan David
Director · Appointed 13 May 2024
British
Born August 1961 (65)
Kendall, John Michael, Professor
Director · Appointed 13 May 2024
British,Canadian
Born December 1962 (63)
Ownership 1 active
People and entities with significant control, from the Companies House PSC register
Corporate entity · Notified 18 October 2024
Owns 25–50% of shares
Holds 25–50% of voting rights
Corporate
Reg. no. 09093331
Former controllers (2)
18 October 2024
Ceased Jonathan David Blundy — Owns 25–50% of shares
1 July 2024
Ceased John Michael Kendall — Owns 25–50% of shares
Group structure 17 shown
Ownership group derived from the Companies House PSC register
Acionna Therapeutics Ltd Owns 50–75% of shares
Animal Dynamics Limited Owns 50–75% of shares
Archangel Lightworks Ltd Owns 25–50% of shares
Ascension Earth Resources Ltd This company Owns 25–50% of shares
Caudal Energy Limited Owns 25–50% of shares
Caudal Morlais Limited Owns 75–100% of shares
Circadian Therapeutics Limited Owns 75–100% of shares
Cora Biosciences Limited Owns 25–50% of shares
Credo Therapies Ltd Owns 50–75% of shares
Densix Limited Owns 25–50% of shares
Dyna Therapeutics Limited Owns 50–75% of shares
Eligentis Limited Owns 25–50% of shares
Evox Therapeutics Limited Owns 25–50% of shares
Fluorok Limited Owns 25–50% of shares
Financials
Balance sheet as at 31 May 2025 · total exemption full accounts
- Cash
- £3,825,936
- Current Ratio
- 76.7x
Balance sheet detail
| 2025 | |
|---|---|
| Fixed Assets | £431,501 |
| Current Assets | £3,953,167 |
| Debtors | £127,231 |
| Cash | £3,825,936 |
| Creditors (< 1 year) | £51,548 |
| Net Current Assets | £3,901,619 |
| Shareholder Funds | £4,333,120 |
Filings
Recent filings only. See the full history on Companies House
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 3 November 2026 | Registered office address changed | |||
| 3 November 2026 | Registered office address changed | |||
| 30 October 2026 | Satisfaction of a charge in full | |||
| 27 October 2026 | Appointment of a director |
Other companies in this industry
London
London
London
London
London
London
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →